Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock

February 13, 2026 by InsiderTrades.com

Key Points

On Feb 10, CEO Neil Kumar sold 40,000 shares at an average price of $71.94 for about $2.88 million, reducing his stake by 5.44% to 695,686 shares still valued near $50.0 million.
The Feb 10 sale continues a pattern of recent insider disposals (40,000 on Jan 8; 30,011 on Dec 15; 40,000 on Dec 4; 26,156 on Nov 20), indicating sustained insider monetization.
Separately, BridgeBio announced positive Phase 3 PROPEL 3 topline results for oral infigratinib—primary endpoint met with favorable safety and plans for NDA/MAA submissions in H2 2026—driving analyst upgrades and share gains despite near‑term earnings and cash‑flow risks.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the firm's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total transaction of $2,877,600.00. Following the transaction, the chief executive officer owned 695,686 shares of the company's stock, valued at $50,047,650.84. This trade represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope

Neil Kumar also recently made the following trade(s):

On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $73.97, for a total transaction of $2,958,800.00.
On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.64, for a total transaction of $2,240,021.04.
On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.40, for a total transaction of $2,976,000.00.
On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The shares were sold at an average price of $65.84, for a total value of $1,722,111.04.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $76.06 on Friday. The business's fifty day moving average price is $75.57 and its two-hundred day moving average price is $62.88. The stock has a market cap of $14.66 billion, a PE ratio of -18.20 and a beta of 1.13. BridgeBio Pharma, Inc. has a one year low of $28.33 and a one year high of $84.94.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently bought and sold shares of BBIO. Strs Ohio increased its position in BridgeBio Pharma by 1.1% during the third quarter. Strs Ohio now owns 18,600 shares of the company's stock worth $966,000 after purchasing an additional 200 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of BridgeBio Pharma by 28.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company's stock valued at $53,000 after buying an additional 227 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company's stock worth $54,000 after buying an additional 228 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of BridgeBio Pharma by 4.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock worth $396,000 after buying an additional 244 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after acquiring an additional 245 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: PROPEL 3 topline: primary endpoint met (AHV) with a mean treatment difference vs placebo of +2.10 cm/yr (LS mean +1.74 cm/yr), key secondary endpoints positive, favorable safety, and plans for NDA/MAA submissions H2 2026 — a clear de‑risking step toward commercialization. BridgeBio Reports Positive Phase 3 Topline Results
Positive Sentiment: Analyst / market reaction: multiple outlets and analysts (e.g., Jefferies reported the data as “compelling”) pushed the shares higher on expectations the data materially improves the drug’s commercial and regulatory prospects. BridgeBio Pharma shares rise on ‘compelling' Phase 3 trial results
Positive Sentiment: Competitive impact: positive infigratinib data pressured rival programs (reports noted BioMarin and Ascendis shares fell), suggesting BridgeBio’s result may shift market share expectations in the achondroplasia space. BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data
Neutral Sentiment: Short-interest data in feeds shows zero shares (likely a data glitch or reporting lag) — not currently informative about bearish positioning. (Source: short-interest entries reported to data services.)
Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M value), which may be viewed negatively by some investors despite continued significant insider holdings. SEC Form 4 — Neil Kumar sale
Negative Sentiment: Earnings/near-term financials: Zacks flagged BridgeBio as likely to report negative earnings for the upcoming quarter, so while the clinical win is material, near-term P&L expectations and cash needs remain risks for the equity. BBIO May Report Negative Earnings — Zacks

Analyst Upgrades and Downgrades

BBIO has been the subject of several analyst reports. Truist Financial boosted their target price on shares of BridgeBio Pharma from $80.00 to $86.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Piper Sandler lifted their price target on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an "overweight" rating in a report on Thursday, October 30th. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a research note on Thursday, December 11th. They set an "outperform" rating and a $94.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of BridgeBio Pharma in a research report on Monday, November 3rd. Finally, Evercore reiterated an "outperform" rating on shares of BridgeBio Pharma in a report on Monday, October 27th. Twenty-two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.95.

View Our Latest Stock Analysis on BBIO

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.